Aviva hikes dividend 10% and unveils £350m buyback as 2026 targets delivered early

Aviva delivered a strong 2025 with group operating profit up 25% to £2.2bn, IFRS ROE rising to 17.5% (from 15.7%), and cash remittances up 4% to just over £2bn; general insurance premiums grew 18% to £14.1bn aided by the Direct Line acquisition while the wealth division holds over £230bn of assets with ~£11bn net inflows. The board raised the final dividend 10% to 26.2p and announced a £350m share buyback, and set new 2026–28 targets (11% annual operating EPS growth to 2028, IFRS ROE >20%, and cumulative cash remittances >£7bn), signalling continued earnings momentum and meaningful capital returns support for the equity.

Analysis

Market structure: Aviva’s results and £350m buyback shift incremental market share and capital return leadership toward diversified UK insurers (LSE:AV). Winners include Aviva (AV.L), asset managers feeding its wealth platform, and bondholders benefiting from stronger credit metrics; losers are pure-play general insurers with weaker distribution (e.g., ADM.L) who face pricing pressure as Aviva leverages scale and Direct Line’s book to compress acquisition costs. The announcement signals tighter supply of free-float (buyback) and higher expected equity cash returns (target >20% ROE by 2028), implying a re-rate of insurance multiples if achieved within 12–36 months.

Risk assessment: Key tail risks are integration failure of Direct Line causing reserve shocks, UK regulator (PRA) capital demands or consumer redress, and a market shock that reverses £11bn net inflows into wealth products; each could shave >200–400bps off ROE in a stress year. Short-term (days–weeks) reaction will track buyback execution news and any PRA comments; medium-term (6–18 months) sensitivity to investment returns and lapse/claims trends is critical; long-term hinges on delivering the 11% EPS CAGR to 2028. Hidden dependencies: wealth inflows depend on continued UK saver confidence and rates; buybacks can mask underwriting margin deterioration.

Trade implications: Primary trade is selective long Aviva (AV.L) exposure sized 2–3% of equity portfolio, target 15–25% total return over 12 months, stop loss 12% on negative catalyst (PRA/earnings miss). Pair trade: long AV.L vs short LGEN.L (Legal & General) 1:1 to express preference for Aviva’s capital returns and growth vs LGEN’s exposure to margin compression in retail savings over 6–18 months. Options: consider a 12-month AV.L 10% OTM bull-call spread to cap cost or sell staggered 6–12 month puts 8–12% OTM to collect yield if comfortable owning at that level.

Contrarian angles: Consensus may underweight execution risk; the market could be underpricing a scenario where buyback pace slows or wealth flows revert (a 1–2% AUM outflow would materially hit fee income). Historical parallel: prior insurer buyback-fueled reratings reversed when underwriting or regulatory shocks appeared (2008–2012 cycles); therefore monitor capital ratios and PRA dialogue closely as early warning. Unintended consequence: aggressive buybacks reduce balance sheet buffer, increasing sensitivity to a single severe claims year — a governance/regulatory flashpoint that would re-rate the stock quickly.

Key Decisions for Investors

• Establish a 2–3% long position in Aviva (LSE:AV) within 5 trading days, target 15–25% total return over 12 months driven by dividend + buyback + re-rating; set a hard stop at -12% and trim half position on +12% gain.
• Implement a 1:1 pair trade: long AV (2% portfolio) vs short LGEN.L (2%); hold 6–18 months to play Aviva’s superior ROE and buyback vs Legal & General’s margin/cash flow risk; cover if AV misses EPS guidance or PRA raises capital concerns.
• Buy a 12-month AV call spread (buy 10% OTM, sell 30% OTM) sized to 0.5–1% portfolio to leverage upside while limiting premium; alternatively sell 6–12 month cash-secured puts 8–12% OTM to generate ~mid-single-digit annualized yield if willing to acquire shares at a discount.
• Reduce or avoid exposure to pure-play general insurers (e.g., ADM.L) by 1–2% of portfolio and rotate into UK diversified insurers and wealth managers; reassess after Q2 2026 trading updates and any PRA communications within 30–60 days.